The selection of a nectin-2-positive cancer using companion diagnosis and determination of H-score, which quantitates the intensity and proportion of nectin-2 expression, would provide a better therapeutic option for ovarian cancer patients for the application of anti-nectin-2 ADC as a monotherapy or the combination of anti-nectin-2 ADC with chemotherapy. The gene discussed is NECTIN2; the disease is cancer.